Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: Patients with~* Clinical significant alcohol intake history (men over 50g within 3 months, women over 40g within 3 months)~* modified DF score greater than or equal to 32~* Transjugular liver biopsy shows typical feature of alcoholic hepatitis or meet the clinical diagnosis (total serum bilirubin level over 5 mg/dL, aspartate aminotransferase/alanine aminotransferase ratio \>2, aspartate aminotransferase \< 300 IU/L)~* Included patients should meet the all above criteria and Lille score \> 0.16 at the day 7 of prednisolone 40mg (or 32 mg of methylprednisolone) daily treatment.~Exclusion Criteria: Patients with~* hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV), or anti-human immunodeficiency virus (HIV) (+)~* Malignancy including hepatocellular carcinoma~* Portal vein thrombosis, hemochromatosis, autoimmune hepatitis, Wilson's disease, alpha-1-antitrypsin deficiency~* Pregnancy, breast feeding, or who refuses contraception, or who cannot do contraception~* History of adverse event including allergic response, hypersensitivity to G-CSF~* Hypovolemic shock due to gastrointestinal hemorrhage or who need packed red blood cell (RBC) transfusion more than 3 units or increased modified discriminant factor (DF) score greater or equal to 32 from below 32 due to gastrointestinal hemorrhage~* Sepsis or uncontrolled acute infection~* Hepatic encephalopathy grade 3-4~* History of steroid or pentoxifylline treatment within 3 months~* Myeloblast on peripheral blood smear test~* Critical comorbidities (type I hepatorenal syndrome, serum creatinine \>2.5mg/dL, heart failure, pulmonary disease, psychiatric disease, acute pancreatitis etc.)~* Who refuses to participate in clinical trial

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- G-CSF + steroid in partial responder (Type: EXPERIMENTAL): Patients who are randomized to prednisolone plus G-CSF treatment group in patients with partial responder to prednisolone therapy.
- Placebo + steroid in partial responder (Type: PLACEBO_COMPARATOR): Patients who are randomized to prednisolone plus placebo treatment group in patients with partial responder to prednisolone therapy.
- G-CSF in null responder to steroid (Type: EXPERIMENTAL): Patients who are randomized to G-CSF treatment group in patients with null responder to prednisolone therapy.
- Placebo in null responder to steroid (Type: PLACEBO_COMPARATOR): Patients who are randomized to placebo treatment group in patients with null responder to prednisolone therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).